



the **Hydroponics** company

www.thcl.com.au

ASX RELEASE (20<sup>th</sup> November)

# THC ENTERS PARTNERSHIP WITH ISRAELI CANNABIS PIONEER BOLPHARMA

## Key Points:

- **THC's subsidiary Candeo Limited locks in off-shore supply for medicinal cannabis by entering into a partnership with BOL Pharma**
- **BOL Pharma is one of Israel's leading medicinal cannabis producers with an extensive portfolio of products targeted for specific clinical applications**
- **THC executes on its dual import/domestic medicinal cannabis supply chain**
- **THC remains on track to complete its domestic R&D and growing facility**
- **BOL Pharma to initiate a clinical trial with Candeo**
- **BOL Pharma to expand its current multiple indications into Australia through its partnership with Candeo**

**The Hydroponics Company Limited** (ASX:THC) ("THC") is pleased to announce that its wholly owned subsidiary Candeo Limited entered into a Letter of Intent (LOI) with leading Israeli medicinal cannabis group BOL Pharma Limited (**BOL**) for the supply of cannabinoid related products in Australia.

THC's Group Chief Executive Officer, David Radford said: "We are delighted to be partnering with BOL, a respected industry leader in Israel, for access to high quality targeted medicinal cannabis products. This agreement reinforces our commitment to a dual supply strategy, importing some of the best cannabinoid related products to Australia, while cultivating our own medicinal cannabis strains in Australia. We look forward to developing this long term relationship."

BOL Pharma has agreed to supply all products required for an initial clinical trial with the long term view of providing products for additional clinical trials that are targeting to take place during 2018.



The Hydroponics Company Limited  
(ASX:THC) ACN: 614 508 039

Suite 305, Level 3, 35 Lime St  
Sydney, NSW, Australia. 2000.

Tamir Gedo, Chief Executive Officer of BOL Pharma said: “This agreement kicks off BOL Pharma’s entry into Australia’s emerging medical cannabis market and supports our goal of bringing clinically verified cannabinoid treatments to patients around the world. We are completely aligned with Candeo’s objective of providing high quality, validated medical cannabis products to Australia and expect this agreement is just the beginning of long and productive collaboration.”

BOL Pharma (**BOL**) has been pioneering the creation of the medical cannabis industry in Israel since 2007. The company sources 99% pure pharma grade CBD, THC, and other cannabinoids from its own GAP certified cultivation facilities and GMP certified production facility. Working in conjunction with Israel’s Ministry of Health and under governmental license, BOL serves thousands of patients, doctors, HMOs, and hospitals providing cannabis based medical products and cannabinoid active pharmaceutical ingredients (APIs). BOL produces formulations for clinical research and white label services for the pharmaceuticals, supplements, and cosmetics industries.

Candeo will continue the active development of the medicinal cannabis market in partnership with **BOL** as it looks to build the developing Australian market. In parallel the Company continues to develop its local production and research capabilities in Australia now that it has received both a Medicinal Cannabis Research Licence as well as Medicinal Cannabis Licence from the Office of Drug Control.

**For further information, please contact:**



David Radford  
Group Chief Executive Officer  
The Hydroponics Company Limited

Suite 305, Level 3, 35 Lime Street  
Sydney, NSW 2000 Australia

**P:** +61 2 9251 7177  
**M:** +61 407 218 922  
**E:** [davidr@thcl.com.au](mailto:davidr@thcl.com.au)



Michael Lovesey  
Director Corporate Media Relations  
MMR Corporate Services Pty Ltd

Level 2, 131 Macquarie Street  
Sydney, NSW 2000 Australia

**P:** +61 2 9251 7177  
**M:** +61 449 607 636  
**E:** [michaell@mmercortate.com](mailto:michaell@mmercortate.com)

**About BOL Pharma** [www.bolpharma.com](http://www.bolpharma.com)

BOL Pharma (**BOL**) has been pioneering the creation of the medical cannabis industry in Israel since 2007. The company sources 99% pure pharma grade CBD, THC, and other cannabinoids from its own GAP certified cultivation facilities and GMP certified production facility. Working in conjunction with Israel's Ministry of Health and under governmental license, BOL serves thousands of patients, doctors, HMOs, and hospitals providing cannabis based medical products and cannabinoid active pharmaceutical ingredients (APIs). BOL produces formulations for clinical research and white label services for the pharmaceuticals, supplements, and cosmetics industries.

**About The Hydroponics Company** [www.thcl.com.au](http://www.thcl.com.au)

THC is at the forefront of developing a leading, diversified worldwide cannabis business, focusing on two core business units: Development and delivery of medicinal cannabis, and manufacturing and distribution of hydroponics equipment, materials and nutrients.

**About Canndeo Ltd** [www.canndeo.com](http://www.canndeo.com)

Canndeo is a wholly-owned subsidiary of THC that operates under a pharmaceutical model with a focus on the end-to-end supply of medicinal cannabis products. THC has leading expertise in breeding, growth and extraction capability with a focus on the rapid introduction of medicinal cannabis products. It has received its Medicinal Cannabis Research Licence in July, 2017 and its Medicinal Cannabis Licence in Oct 2017. Canndeo leverages +17 years of Cannabis sativa breeding, variety selection and growth management. Canndeo will target multiple medical markets with high purity cannabidiol (CBD), a new class of medicinal product that can be used to target dementia, epilepsy and other neurological disorders.